Telix Pharmaceuticals plans to spin off its wholly-owned subsidiary Rhine Pharma and structure it as an independent company.
Rhine Pharma’s mission will be to expand global access to radiopharmaceuticals for cancer imaging and treatment using two generator-produced isotopes, technetium-99m (Tc-99m) and rhenium-188 (Re-188), the company said.
Rhine Pharma was formed through a collaboration between Telix and Heidelberg University Hospital that aimed to develop a ligand that targets prostate cancer that could be labeled with either Tc-99m for SPECT imaging or Re-188 for radioligand therapy. The collaboration resulted in a potential theranostic compound, RHN0014, which the company is now advancing into a phase I/IIa clinical study.
